-
JPM2022: Ready to go, the legendary creature BCMA CAR-T is about to enter the runway, Yi Mai Meng broke the news
Time of Update: 2022-01-24
If cilta-cel is finally approved by the FDA, it is expected to become the second CAR-T cell therapy targeting BCMA in the world, which will bring new options for the treatment of r/r MM .
-
Merck's new crown oral drug will soon be approved by the European Union
Time of Update: 2021-11-15
Merck's oral new crown treatment drug Molnupiravir (Molnupiravir) The European Medicines Agency stated that the decision to initiate the rolling review was based on preliminary results of laboratory and clinical studies .
-
CSPC will win $9 billion star anticoagulant
Time of Update: 2021-11-05
In 2020, Bristol-Myers Squibb’s Eliquis global sales exceeded 9 billion U.
In 2020, Bristol-Myers Squibb's Eliquis (apixaban tablets) global sales exceeded 9.
Bristol-Myers Squibb Eliquis global sales (unit: million dollars)Source: Mynet.
-
Carrying out popular science publicity, the national medical device safety publicity week is highly enthusiastic
Time of Update: 2021-08-15
Event Overview On July 19, 2021 "National Medical Device Safety Publicity Week" was launched in Beijing, with the theme of "Innovative Development of Safe Use of Devices".
-
WuXi Innolux Announces 2020 Annual Results
Time of Update: 2021-07-13
In June 2020, we submitted a new drug application (NDA) for relmacabtagene autoleucel (relma-cel) as a third-line therapy for diffuse large B-cell lymphoma (DLBCL) to the National Medical Products Administration (NMPA).
For the year ended December 31, 2020, we incurred sales expenses of RMB 13.
-
Spark investors cut their holdings as Roche trading was delayed again
Time of Update: 2021-03-01
"In order to give the Federal Trade Commission (FTC) and the UK Competition and Markets Authority (CMA) more time to complete the review, the bid period for Spark shares has been extended from the current deadline of November 25 to December 10," Roche said on Friday.
-
Research and development daily Sanofi "Du Puliu monoanti" new adaptive disease was approved clinically
Time of Update: 2021-01-11
2020.12.29 Research and Development NEWS: Phase 3 clinical success in the treatment of central neuropathological pain after spinal cord injury; AstraZeneone/Merca East Targeted Anti-Cancer Drug obtained 3 approvals in Japan; and Huang Pharmaceuticals submitted a listing application to the FDA for Sofantini; Novartis announced that a new drug for allergic conjunctivitis has been officially approved in China...
-
Lizhu Group injection with Danqulin sodium was approved for the domestic first imitation
Time of Update: 2020-10-29
On October 24, Lizhu Group announced that its subsidiary Lizhu Pharmaceutical Factory received the "Drug Registration Certificate" for injection of Danqulin sodium, which was approved for listing for the prevention and treatment of malignant hyperthermal fever.
-
Coming! Hausen takes the lead in Qilu, and the heavyweight DPP-4 inhibitor is officially approved for the first time
Time of Update: 2019-03-29
Recently, Jiangsu Haosen Pharmaceutical Co., Ltd.'s viagretine tablet was approved with the approval number of gjzz h20193060 Viagliptin is the second DPP-4 inhibitor on the market in the world to red
-
20 days from application to approval! FDA's new pilot program to accelerate the evaluation of anticancer drugs
Time of Update: 2018-07-19
Today, the U.S FDA approved kiscali (ribociclib) and aromatase inhibitor (AI) of Novartis as the initial endocrine therapy for premenopausal or postmenopausal women with hormone receptor (HR) positive
-
Research group of Professor Xiao Lehui of Nankai University: using single particle optical microscopy to explore the uptake mechanism of nanoparticles in different dimensions at the living cell level
Time of Update: 2018-06-08
Due to its unique size, good biocompatibility and easy functionalization, lead nanomaterials have been widely concerned in the past decades Especially in the field of biology, they can integrate imagi
-
CFDA and Zhejiang Provincial Bureau sign cooperation agreement on deepening drug review system reform and innovative services
Time of Update: 2018-02-07
Source: in the morning of February 2, 2018, the drug review center of the State Food and Drug Administration and the Provincial Bureau signed the "cooperation agreement on deepening the reform of drug
-
Notice: the content of "academic news" column is upgraded, and the latest paper information of mainstream journals is updated every day
Time of Update: 2017-05-23
In order to provide researchers with the most complete and fresh paper news, the CBG "academic news" column was launched with new content: daily updates of JACS, angelw, organizational letters, Journa
-
Accelerated review, Sanofi and Regeneron spent US$67.5 million to purchase priority coupons
Time of Update: 2014-08-06
Source: chuminhua 2014-08-06: in order to beat competitors and get cholesterol lowering drug alirocumab on the market faster, Sanofi and regeneron, two companies, spent an unprecedented US $67.5 milli
